v3.26.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenue:        
Total revenue $ 131,948 $ 86,679 $ 249,648 $ 171,364
Operating expenses:        
Research and development 22,376 16,830 43,792 35,354
Sales and marketing 33,441 24,279 63,814 47,270
General and administrative 40,908 27,683 71,392 50,452
Gain on sale of lab products business   0 (112,966) 0
Litigation settlement expense 0 350 600 5,710
Total operating expenses 18,725 97,800 135,227 195,859
Income (loss) from operations 113,223 (11,121) 114,421 (24,495)
Other income:        
Interest income, net 1,735 2,364 3,644 5,148
Other (expense) income, net (440) 72 (770) 367
Total other income 1,295 2,436 2,874 5,515
Income (loss) before income taxes 114,518 (8,685) 117,295 (18,980)
Income tax (expense) benefit (3,882) 117 (3,850) 59
Net income (loss) $ 110,636 $ (8,568) $ 113,445 $ (18,921)
Net income (loss) per share (Note 3):        
Basic (in usd per share) $ 2.15 $ (0.16) $ 2.21 $ (0.35)
Diluted (in usd per share) $ 2.07 $ (0.16) $ 2.13 $ (0.35)
Weighted-average shares used to compute net income (loss) per share:        
Basic (in shares) 51,469,375 54,304,754 51,311,462 54,781,601
Diluted (in shares) 53,422,523 54,304,754 53,320,018 54,781,601
Testing services revenue        
Revenue:        
Total revenue $ 99,927 $ 62,033 $ 191,325 $ 123,954
Operating expenses:        
Cost of testing services, product, patient and digital solutions 15,918 15,406 33,015 30,519
Product revenue        
Revenue:        
Total revenue 12,791 11,833 23,137 22,643
Operating expenses:        
Cost of testing services, product, patient and digital solutions 4,342 4,981 9,176 10,567
Patient and digital solutions revenue        
Revenue:        
Total revenue 19,230 12,813 35,186 24,767
Operating expenses:        
Cost of testing services, product, patient and digital solutions $ 14,706 $ 8,271 $ 26,404 $ 15,987